{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:57:12Z","timestamp":1774004232542,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.isci.2025.114327","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:45:03Z","timestamp":1764780303000},"page":"114327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of BTG1 for predicting decitabine sensitivity in de novo acute myeloid leukemia"],"prefix":"10.1016","volume":"29","author":[{"given":"Shiyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiwen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-9638","authenticated-orcid":false,"given":"Donghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114327_bib1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.114327_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114327_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2025.114327_bib4","first-page":"1521","article-title":"Clinical efficacy of decitabine-containing induction chemotherapy in de novo non-elderly acute myeloid leukemia","volume":"56","author":"Zheng","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.isci.2025.114327_bib5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ajh.26206","article-title":"Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia","volume":"96","author":"Kadia","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2025.114327_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/leu.2015.244","article-title":"A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"30","author":"Daver","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114327_bib7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114327_bib8","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-019-11413-4","article-title":"Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML","volume":"10","author":"Oellerich","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114327_bib9","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1002\/jcp.27407","article-title":"Tumor suppressors BTG1 and BTG2: Beyond growth control","volume":"234","author":"Yuniati","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.isci.2025.114327_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.aax0194","article-title":"mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence","volume":"367","author":"Hwang","year":"2020","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.isci.2025.114327_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2016.153023","article-title":"Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients","volume":"102","author":"Scheijen","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2025.114327_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/PAP.0b013e3182169948","article-title":"MYC and aggressive B-cell lymphomas","volume":"18","author":"Slack","year":"2011","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.isci.2025.114327_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.598192","article-title":"BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial-Mesenchymal Transition","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114327_bib14","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1186624","article-title":"The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML","volume":"327","author":"Wang","year":"2010","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.isci.2025.114327_bib15","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.18632\/aging.102973","article-title":"Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML","volume":"12","author":"Hong","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.isci.2025.114327_bib16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2025.114327_bib17","article-title":"Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma","volume":"125","author":"Xu","year":"2020","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.isci.2025.114327_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173894","article-title":"TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients","volume":"895","author":"Liu","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114327_bib19","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1002\/pmic.200400968","article-title":"Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia","volume":"4","author":"Cho","year":"2004","journal-title":"Proteomics"},{"key":"10.1016\/j.isci.2025.114327_bib20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41418-019-0389-3","article-title":"Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis","volume":"27","author":"Liu","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.isci.2025.114327_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00280-018-3536-5","article-title":"Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt\/\u03b2-catenin\/Endothelin-1 axis via activating B cell translocation gene 1","volume":"81","author":"Yin","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.isci.2025.114327_bib22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114327_bib23","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.114327_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114327_bib26","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114327_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41408-021-00591-4","article-title":"Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes","volume":"11","author":"Yu","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2025.114327_bib28","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s11427-019-1610-2","article-title":"Impact of prophylactic\/preemptive donor lymphocyte infusion and intensified conditioning for relapsed\/refractory leukemia: a real-world study","volume":"63","author":"Wang","year":"2020","journal-title":"Sci. China Life Sci."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422502588X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422502588X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:42:13Z","timestamp":1773996133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258900422502588X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S258900422502588X"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114327","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of BTG1 for predicting decitabine sensitivity in de novo acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114327"}}